Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Calidad del sueño preoperatoria y resultados postoperatorios en cirugía de mama

16 de noviembre de 2026 actualizado por: Mustafa Kemal ŞAHİN, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Association of Preoperative Sleep Quality With 24-Hour Systemic Immune-Inflammation Index, Early PACU Pain, and Analgesic Use After Breast Cancer Surgery

This prospective, single-center observational study examined the association between preoperative sleep quality and postoperative outcomes in women undergoing elective breast cancer surgery. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), with scores ≤5 indicating good sleep quality and scores >5 indicating poor sleep quality.

The primary outcome was the systemic immune-inflammation index (SII), calculated from routine blood counts obtained 24 hours after surgery. Postoperative SII was compared between sleep-quality groups, accounting for preoperative SII and relevant clinical and surgical characteristics. Secondary outcomes included change in SII from baseline, pain intensity during the first 45 minutes in the post-anesthesia care unit (PACU), opioid consumption, rescue analgesic requirement, and length of hospital stay. Pain was assessed using a 10-cm visual analogue scale on PACU arrival and at 15, 30, and 45 minutes. Opioid consumption included morphine and tramadol administered during the final 20 minutes of surgery and the first 45 minutes in the PACU, expressed as intravenous morphine equivalents.

No treatment was assigned by the study protocol. Anesthetic and analgesic management followed routine clinical practice.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

This prospective observational study was conducted at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital in Ankara, Turkey, among women undergoing elective breast cancer surgery under general anesthesia. Procedures included lumpectomy or mastectomy, with axillary dissection when clinically indicated. The study examined whether preoperative sleep quality was associated with postoperative systemic immune-inflammation index (SII), immediate postoperative pain, and analgesic use.

Preoperative sleep quality was assessed using the validated Turkish version of the Pittsburgh Sleep Quality Index (PSQI). The total score ranges from 0 to 21, with higher scores indicating poorer sleep quality. Patients were classified as having good sleep quality (PSQI ≤5) or poor sleep quality (PSQI >5). Demographic characteristics, comorbidities, oncological history, surgical characteristics, and perioperative clinical data were recorded prospectively.

The primary outcome was SII measured 24 hours (±6 hours) after surgery, calculated as platelet count × neutrophil count / lymphocyte count. Preoperative SII was calculated using the same formula. The primary analysis compared postoperative SII between sleep-quality groups, adjusting for baseline SII and clinical and surgical covariates. Change in SII, calculated as postoperative minus preoperative SII, was a secondary outcome.

Pain intensity was assessed using a 10-cm visual analogue scale (VAS), anchored at "no pain" and "worst imaginable pain." Patients marked their pain intensity on the line; the distance from the zero anchor was measured and rounded to the nearest whole centimeter. Assessments were performed on arrival in the post-anesthesia care unit (PACU) and at 15, 30, and 45 minutes. Maximum VAS was defined as the highest score across the four scheduled assessments. The pain assessor was unaware of patients' PSQI scores and sleep-quality groups.

Anesthetic and analgesic management followed routine clinical practice, with no treatment assigned by the study protocol. Intravenous morphine or tramadol was administered for postoperative analgesia during the final 20 minutes of surgery. Rescue analgesia consisted of intravenous morphine or tramadol when the PACU VAS score was ≥4; drug selection and dosing were determined by the treating anesthesiologist. Scheduled pain assessments continued after rescue treatment. No regional blocks or surgical local anesthetic infiltration were performed.

Total opioid consumption comprised morphine and tramadol administered during the final 20 minutes of surgery and the first 45 minutes in the PACU. Intravenous tramadol doses were converted to intravenous morphine equivalents using a factor of 0.1 and added to the administered morphine dose. Fentanyl used for induction and remifentanil used for maintenance were excluded from this measure. Rescue analgesic requirement was defined as receipt of at least one rescue opioid dose during the PACU observation period. The planned 24-hour pain and opioid outcomes could not be reliably evaluated because of follow-up limitations and incomplete opioid documentation. The reported analyses were therefore restricted to PACU pain during the first 45 minutes and opioid administration during the final 20 minutes of surgery and this PACU period. Length of hospital stay was also recorded.

Secondary analyses evaluated PSQI total score as a continuous predictor of postoperative SII, maximum VAS, total opioid consumption, and rescue analgesic requirement. Adjustment variables included age, body mass index, ASA physical status III, chronic disease burden, chemotherapy within the previous year, axillary dissection, and operation duration. Breast surgery type was added to the models during manuscript revision. Preoperative SII was included only in the postoperative SII models. Individual covariate-outcome associations were interpreted as exploratory.

Tipo de estudio

De observación

Inscripción (Actual)

156

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Ankara, Turquía (Türkiye), 06200
        • Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Reanimation

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Método de muestreo

Muestra no probabilística

Población de estudio

The study population included women aged 18-75 years who underwent elective breast cancer surgery at a tertiary oncology center. Procedures included breast-conserving surgery (lumpectomy) or mastectomy, with or without axillary dissection. Preoperative sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). All patients received routine perioperative care, and no treatment was assigned by the study protocol. This observational study examined the association between preoperative sleep quality and postoperative outcomes in routine clinical practice.

Descripción

Inclusion Criteria:

  • Female patients aged 18 to 75 years
  • Scheduled for elective breast cancer surgery
  • American Society of Anesthesiologists (ASA) physical status I to III
  • Able to understand and complete the Pittsburgh Sleep Quality Index (PSQI)
  • Willing to participate in the study
  • Provided written informed consent

Exclusion Criteria:

  • Active infection
  • History of chronic inflammatory disease or autoimmune disease
  • Use of steroids or immunosuppressive drugs within the past 6 months
  • Known diagnosis of obstructive sleep apnea syndrome
  • Severe cognitive impairment preventing completion of the questionnaire
  • Planned emergency surgery
  • Refusal to participate or failure to provide informed consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Good Sleep Quality (PSQI ≤ 5)

Patients with good preoperative sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score ≤5, were included in this cohort. Sleep quality was assessed preoperatively using the validated PSQI questionnaire. No treatment was assigned by the study protocol, and patients received routine perioperative care. Postoperative SII, pain intensity, and analgesic consumption were compared with those in the poor-sleep-quality group.

Preoperative sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated self-reported questionnaire covering the preceding month. Patients were classified into two cohorts: good sleep quality (PSQI ≤5) and poor sleep quality (PSQI >5). The PSQI assessment was used for grouping and analysis. No treatment was assigned by the study protocol, and perioperative management followed routine clinical practice.

Otros nombres:
  • Índice de Calidad del Sueño de Pittsburgh (PSQI)
Poor Sleep Quality (PSQI > 5)

Patients with poor preoperative sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score >5, were included in this cohort. Sleep quality was assessed preoperatively using the validated PSQI questionnaire. No treatment was assigned by the study protocol, and patients received routine perioperative care. Postoperative SII, pain intensity, and analgesic consumption were compared with those in the good-sleep-quality group.

Preoperative sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated self-reported questionnaire covering the preceding month. Patients were classified into two cohorts: good sleep quality (PSQI ≤5) and poor sleep quality (PSQI >5). The PSQI assessment was used for grouping and analysis. No treatment was assigned by the study protocol, and perioperative management followed routine clinical practice.

Otros nombres:
  • Índice de Calidad del Sueño de Pittsburgh (PSQI)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Postoperative Systemic Immune-Inflammation Index (SII)
Periodo de tiempo: At 24 hours postoperatively (± 6 hours)

The primary outcome was the postoperative systemic immune-inflammation index (SII), calculated from routine complete blood count measurements obtained 24 hours after surgery. SII was calculated using the formula: platelet count × neutrophil count / lymphocyte count. Postoperative SII was compared between patients with poor (PSQI >5) and good (PSQI ≤5) preoperative sleep quality, adjusting for preoperative SII and clinical and surgical covariates.

At 24 hours postoperatively (± 6 hours)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Systemic Immune-Inflammation Index (ΔSII)
Periodo de tiempo: From the preoperative assessment to 24 hours after surgery.

Change in SII was calculated as postoperative SII minus preoperative SII. SII was calculated at both time points as platelet count × neutrophil count / lymphocyte count. Changes were compared between patients with good (PSQI ≤5) and poor (PSQI >5) preoperative sleep quality.

From the preoperative assessment to 24 hours after surgery.
Immediate Postoperative Pain Intensity
Periodo de tiempo: On arrival in the post-anesthesia care unit (0 minutes) and at 15, 30, and 45 minutes after arrival.

Pain intensity was assessed using a 10-cm visual analogue scale (VAS), anchored at 0 cm ("no pain") and 10 cm ("worst imaginable pain"). Patients marked their pain intensity on the line, and the measured distance was rounded to the nearest whole centimeter. Scores were recorded at each scheduled assessment, including after rescue analgesia when applicable. Maximum VAS was defined as the highest score across the four assessments

On arrival in the post-anesthesia care unit (0 minutes) and at 15, 30, and 45 minutes after arrival.
Total Opioid Consumption for Postoperative Analgesia
Periodo de tiempo: From 20 minutes before the end of surgery through the first 45 minutes after PACU arrival.

Total opioid consumption was calculated as the sum of intravenous morphine and tramadol administered for postoperative analgesia during the final 20 minutes of surgery and the first 45 minutes in the post-anesthesia care unit (PACU), including rescue doses. Tramadol doses were multiplied by 0.1 to obtain intravenous morphine equivalents and added to the morphine dose. Consumption was expressed in milligrams of intravenous morphine equivalents. Fentanyl administered during induction and remifentanil used for maintenance were excluded.

From 20 minutes before the end of surgery through the first 45 minutes after PACU arrival.
Rescue Analgesic Requirement
Periodo de tiempo: Within the first 45 minutes after arrival in the post-anesthesia care unit.

Rescue analgesic requirement was defined as receipt of at least one intravenous dose of morphine or tramadol during the first 45 minutes in the post-anesthesia care unit (PACU). Rescue analgesia was administered when the visual analogue scale (VAS) score was ≥4. Drug selection and dosing were determined by the anesthesiologist responsible for PACU care. The outcome was recorded as yes/no and summarized as the number and percentage of patients receiving rescue analgesia.

Within the first 45 minutes after arrival in the post-anesthesia care unit.
Postoperative Length of Hospital Stay
Periodo de tiempo: From the date of surgery until hospital discharge, assessed up to 15 days after surgery.

Postoperative length of hospital stay was defined as the duration from the day of breast cancer surgery to hospital discharge, measured in days.

From the date of surgery until hospital discharge, assessed up to 15 days after surgery.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

17 de abril de 2026

Finalización primaria (Actual)

20 de agosto de 2026

Finalización del estudio (Actual)

30 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

17 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

17 de abril de 2026

Publicado por primera vez (Actual)

23 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2026-04/76

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data (IPD) will not be shared. The study involves sensitive clinical data collected from patients in a single-center setting, and data sharing is restricted in order to protect patient confidentiality and comply with institutional and ethical regulations.

De-identified and aggregated data may be available from the corresponding author upon reasonable request, subject to approval by the institutional ethics committee.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .